antibodies for diagnostics News
-
Kephera seeks volunteers who are confirmed COVID-19 positive to donate finger prick blood samples to help develop a new COVID-19 antibody test.
Kephera Diagnostics has launched a new study aimed at collecting blood samples from volunteers at least 18 years of age who have been confirmed positive for COVID-19, for use in development of an antibody test for the virus. The new test will determine whether symptomatic as well as asymptomatic individuals have been infected with the virus that causes COVID-19 by detecting antibodies to ...
-
Dako, an Agilent Technologies Company, Launches Two Ready-to-Use Antibodies for Cancer Diagnosis
Dako, an Agilent Technologies company and worldwide provider of cancer diagnostic solutions, today announced the addition of two new antibodies, Anti-CK 8/18 and Anti-TdT, to the Dako portfolio of high-quality reagents, instruments and software. Anti-CK 8/18 is the first rabbit monoclonal antibody cocktail for cytokeratin 8/18 (CK 8/18) available from a major pathology provider. It is used by ...
-
Calviri, Inc. Receives Exclusive Patent License to Immunosignature Technology, Strengthening Its Disease Diagnostic Capabilities
Calviri, Inc., a biotech startup focused on ending deaths from cancer, announces that Skysong Innovations, the intellectual property management company for Arizona State University (“ASU”), granted Calviri an exclusive license to ASU’s Immunosignature patent portfolio. The portfolio consists of multiple granted and pending patents for the use and optimization of immunosignatures ...
By Calviri
-
Kephera Diagnostics’ new CLIA laboratory launches testing for COVID-19 antibodies
Kephera Diagnostics announced today that it has been approved as a CLIA certified laboratory by the Massachusetts Dept of Public Health and the U.S. Centers for Medicare and Medicaid, and is now offering COVID-19 antibody testing in Massachusetts and 44 other states. Kephera will use an ELISA (Enzyme-Linked Immunosorbent Assay) test that it developed in-house, which is based on the ...
-
Creative Diagnostics Launches New Reagent Solutions for Herpesvirus Research
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced the launch of new reagent solutions for herpesvirus research, including a range of Human Herpesviruses Antibodies designed to help researchers better understand the structure of Herpesvirus entry and develop new treatments and prevention strategies. The Herpesviridae are a large family ...
-
Creative Diagnostics Launches Monkeypox Virus Antigens and Antibodies to Accelerate MPXV Study
Creative Diagnostics, a global leader in offering raw materials, antibodies, and reagents for the bio-technology industry, announced the launch of Monkeypox Virus Antigens and Antibodies to support scientists focused on the research of monkeypox virus. These products are only intended for research use, not for diagnostic or clinical purposes. Monkeypox is a rare disease caused by infection with ...
-
Creative Diagnostics Launches New P53 and Tp53 Antibodies for Cancer Research
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced its extensive portfolio of P53 and TP53 antibodies and solutions to support researchers in the critical field of cancer research. This comprehensive collection of research tools will empower scientists to advance their understanding of P53 and TP53 and their role in cancer development ...
-
PharmAbcine Signs MoU with FutureChem to Explore Possibilities of Developing Novel Radiopharmaceuticals
PharmAbcine Signs MoU with FutureChem to Explore Possibilities of Developing Novel Radiopharmaceuticals PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that it signed an MoU (Memorandum of Understanding) with FutureChem Co., Ltd. (“FutureChem”) (KOSDAQ: 220100ks), a leading ...
-
Creative Diagnostics Launches Monkeypox Virus Antibodies and Antigens to Support MPXV Research
Creative Diagnostics, a global leader in offering raw materials, antibodies, and reagents for the bio-technology industry, announced the launch of several Monkeypox Virus Antibodies and Antigens that have been validated to work in various types of immunoassays and can be used as tools for the detection of Monkeypox viruses. Monkeypox virus (MPV or MPXV) is a double-stranded DNA virus that causes ...
-
Creative Diagnostics Introduces New Nipah Virus Antigens and Antibodies
As a global leading supplier of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently launches a series of NiV recombinant antigen and antibody pairs. All of these new products are produced using standardized production processes to ensure the highest quality. Tests developed using these reagents can assist researchers in routine diagnostics and NiV ...
-
Creative Diagnostics Announces Antigens for Epstein-Barr Virus Antibody Tests
As a global leading supplier of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently launches recombinant antigens p18 and p23 (viral capsid antigens, VCA), p54 and p138 (early antigens, EA) and EBNA1 (nuclear antigen, EBNA). These recombinant antigens in immunoassays are suitable for the detection of IgG and IgM antibodies against EBV in blood ...
-
Creative Diagnostics Expands Its Monoclonal Antibodies Offering to Customers
Creative Diagnostics, a global leader in offering raw materials, antibodies, and reagents for the biotechnology industry, expanded its monoclonal antibodies capabilities and offerings to global customers, including over 1,000 of targets, carrier-free formulations, and conjugated antibodies. Monoclonal antibodies (mAbs) are generated by identical B cells that are cloned from a single parent cell. ...
-
Creative Diagnostics Launches Measles Virus Antigens for the Detection of Antibodies
Creative Diagnostics, a global leader in offering raw materials, antibodies, and reagents for bio-technology industry, recently announced the release of new measles virus antigens suitable for both IgM and IgG detection. These new products are intended for research use only and are not diagnostic use. Measles virus (MeV) is a negative-sense RNA virus with a non-segmented genome and lipid envelope ...
-
Creative Diagnostics Launches New Anti-Small Molecule Label Antibodies to Facilitate NALFIA Development
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has recently announced a series of new Anti-Small Molecule Label Antibodies to facilitate the development of nucleic acid lateral flow immunoassay (NALFIA). These antibodies can specifically bind to small molecule labels and offer customers multiple choices, including Anti Digoxin monoclonal ...
-
Creative Diagnostics Launches Staphylococcal Enterotoxin Antigens
As a global leading supplier of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently launches a range of natural and recombinant staphylococcal enterotoxin antigens that are well validated in double-antibody sandwich enzyme-linked immunosorbent assay (ELISA). The newly introduced antigens consist of five of the most common staphylococcus aureus ...
-
Biosceptre Wins Funding from the UK Government-Backed, SMART Award to Develop Novel Cancer Diagnostic and Therapeutic Targets
Cambridge, UK, 8th February 2016 – Biosceptre, a biopharmaceutical company developing innovative diagnostic and therapeutic approaches to cancer, today announced that the UK government-backed Innovate UK SMART award scheme, has awarded the company £100,000 to support pre-clinical development of diagnostic approaches and antibodies to target Kidney and Lung cancers. This project will ...
-
NEC OncoImmunity AS and Oslo University Hospital team up to develop a diagnostic for COVID-19 using artificial intelligence
NEC OncoImmunity AS (NOI), a subsidiary of NEC Corporation (NEC), and Oslo University Hospital (OUH) are pleased to announce that they have recently been awarded a prestigious grant from the Research Council of Norway (RCN) to develop an artificial intelligence (AI) platform that will enable the rapid design of T-cell diagnostics for emerging or endemic infectious diseases. The project will ...
-
Dako, an Agilent Technologies Company, and Cell Signaling Technology Announce Partnership Within Companion Diagnostics
Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, and Cell Signaling Technology (CST), a worldwide provider of antibodies, today announced that they have entered into a strategic partnership to supply antibodies for use in Dako-branded companion diagnostics products. "We are pleased to work with CST in the development of high-quality, cutting-edge companion ...
-
Thermo Fisher Scientific Response to COVID-19 Expands to Include New Serology Test
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced it will expand its response to the COVID-19 pandemic by developing a total antibodies test in collaboration with WuXi Diagnostics and Mayo Clinic. The new test is the result of ongoing collaboration between all three organizations, including clinical evaluation and support from Mayo Clinic. Thermo Fisher ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you